---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-001787"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T11:13:29.157521+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibikase shareholders approve 5x authorized share increase to 500M and option repricing

## Summary
- Stockholders approved increase in authorized common shares from 100M to 500M; Certificate of Amendment filed Jan 3, 2025.
- Approved elimination of 66 2/3% supermajority vote requirement for amendments to Article IV.
- Approved 27,453,993 share increase in 2020 Equity Incentive Plan reserve.
- Approved repricing of certain outstanding stock options; all proposals passed with >97% of votes cast.
- Vote results: share increase – 62.5M for, 377K against; no broker non-votes.

## SEC filing metadata
- accession: 0001193125-25-001787
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525001787/0001193125-25-001787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525001787/d909904d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-001787
- JSON: https://secwatch.observer/filing/0001193125-25-001787.json
- Plain text: https://secwatch.observer/filing/0001193125-25-001787.txt

## Key facts
- Governance Changes
  Inhibikase Therapeutics, Inc.: Stockholders approved amendments to the Certificate of Incorporation to increase authorized common shares from 100,000,000 to 500,000,000 and eliminate the supermajority vote requirement for amendments to Article IV Section 1 (effective 2025-01-03).
  - Change: charter amendment
  - Effective: 2025-01-03
  source text: A Special Meeting of Stockholders (the “ Special Meeting ”) of Inhibikase Therapeutics, Inc. (the “ Company ”) was held on January 3, 2025. As further described in Item 5.07 to this Current Report on Form 8-K, at the Special Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Certificate of Amendment ”) to increase the number of the Company’s authorized shares of common stock from 100,000,000 shares to 500,000,000 shares and eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof, as described in the Company’s definitive proxy statement filed on November 18, 2024 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The Certificate of Amendment was previously approved by the Company’s board of directors, subject to approval by the Company’s stockholders. On January 3, 2025, the Company filed the Certif
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312525001787/0001193125-25-001787-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.